This exposé embarks on an illuminative journey, unfurling the crucial stratagems imperative for upholding public health, achieved through the unyielding fortress of pharmaceutical quality safeguards
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
The blood test market worldwide is today around $75-80 billion
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Subscribe To Our Newsletter & Stay Updated
